THIS SITE IS NO LONGER BEING UPDATED. PLEASE VISIT OUR NEW SITE: http://braininjuryoutcomes.com
Welcome to the CLEAR III Home Page
CLEAR III is a Phase III randomized clinical trial (RCT) using recombinant tissue plasminogen activator (rtPA, Cathflo® Activase,® Genentech, Inc., San Francisco, CA) to treat subjects with intracerebral hemorrhage (ICH), intraventricular hemorrhage (IVH), and hydrocephalus.
The primary aim of the study is to determine whether rapid removal of IVH clot with low-dose rtPA more likely improves modified Rankin Scores at 6 months (Rankin 0-3) compared to subjects treated with best medical care alone.